Renal effects of recombinant prolactin in anaesthetized rats.
OBJECTIVE
To re-examine the controversial possibility that prolactin exerts renal effects, using recombinant mouse prolactin (rmP), in the presence and absence of circulating vasopressin.


METHODS
In experiment 1, the renal effects of rmP were examined in anaesthetized Brattleboro rats with hereditary hypothalamic diabetes insipidus (BDI) lacking circulating vasopressin and normal animals of the parent Long Evans (LE) strain. In experiment 2, salt and water excretion were studied in fluid-loaded normal Sprague-Dawley (SD) rats, some of which received rmP.


METHODS
In experiment 1, BDI and LE rats maintained in fluid balance were infused i.v. with each of three concentrations of rmP (10, 20 and 40 microg/ml per h) or maintained on 150 mmol/l NaCl vehicle (controls). In experiment 2, the SD rats were infused with 75 mmol/l NaCl in order to induce a state of diuresis comparable to that of BDI rats, some of them then receiving the rmP i.v.


RESULTS
A profound rmP-induced dose-dependent decrease in urine excretion (P<0.005) and a lesser decrease in sodium excretion in the BDI rats was in marked contrast with the small but significant increase in urine excretion in the LE rats compared with controls (P<0.025). The rmP-infused fluid-loaded SD rats also demonstrated a significant (P<0.05) dose-related antidiuresis compared with the control animals, in addition to a decrease in sodium excretion.


CONCLUSIONS
These results show that prolactin has a profound antidiuretic effect in the absence of circulating vasopressin. In contrast, when vasopressin is present in the circulation rmP has a small, but opposite, diuretic effect. Thus the use of a recombinant prolactin has provided evidence for renal effects of this hormone which are modified in the presence of the circulating neurohypophysial hormone vasopressin.
Morrissey
S E
SE
Department of Neuroendocrinology, Division of Neuroscience and Psychological Medicine, Imperial College School of Medicine, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK.
Newth
T
T
Rees
R
R
Barr
A
A
Shora
F
F
Laycock
J F
JF
D018686:Anesthetics, Intravenous / Q000008:administration & dosage; D000818:Animals; D003919:Diabetes Insipidus / Q000097:blood / Q000503:physiopathology / Q000652:urine; D007668:Kidney / Q000187:drug effects* / Q000502:physiology / Q000503:physiopathology; D008297:Male; D011188:Potassium / Q000097:blood / Q000652:urine; D011388:Prolactin / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D011910:Rats, Brattleboro; D020318:Rats, Long-Evans; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D012964:Sodium / Q000097:blood / Q000652:urine; D013874:Thiopental / Q000008:administration & dosage; D014554:Urination / Q000187:drug effects / Q000502:physiology; D014667:Vasopressins / Q000502:physiology
D018686:Anesthetics, Intravenous; D011994:Recombinant Proteins; D014667:Vasopressins; D011388:Prolactin; D012964:Sodium; D013874:Thiopental; D011188:Potassium